{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:38:08Z","timestamp":1793284688563,"version":"4.5.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK13593701A1"],"award-info":[{"award-number":["R01DK13593701A1"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Seven new advanced therapies, belonging to three new classes, have been approved for the treatment of inflammatory bowel diseases (IBD) since 2021. We examined trends in utilization of advanced therapies in the USA since 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using de-identified electronic health record data from 71 US health systems, we examined quarterly trends in utilization of different advanced therapies in patients with ulcerative colitis and Crohn\u2019s disease between 2021 and 2025, using interrupted time-series analysis utilizing Prais\u2013Winsten regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 11\u2009093 patients with ulcerative colitis treated with advanced therapies, we observed an increase in use of upadacitinib (12.1% in Q2\/2025; P\u2009&amp;lt;\u2009.001, compared with first quarter of prescription), interleukin-23p19 (IL23p19) antagonists (5.5%; P\u2009=\u2009.03), and ustekinumab (9.5%; P\u2009=\u2009.04), decline in use of tumor necrosis factor (TNF) antagonists (34.5%; P\u2009=\u2009.003), and stable use of vedolizumab (33.6%; P\u2009=\u2009.17) and sphingosine-1 phosphate receptor modulators (1.6%; P\u2009=\u2009.28). In 15\u2009951 patients with Crohn\u2019s disease treated with advanced therapies, we observed an increase in use of IL23p19 antagonists (15.0% in Q1\/2025; P\u2009=\u2009.003) and upadacitinib (5.9%; P\u2009&amp;lt;\u2009.001) and decline in use of TNF antagonists (50.2%; P\u2009=\u2009.001) and ustekinumab (13.5%; P\u2009&amp;lt;\u2009.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Contemporary trends in advanced therapy utilization in patients with IBD suggest an increased utilization of upadacitinib and anti-interleukins, accompanied by a decline in use of TNF antagonists in the USA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf186","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:50:55Z","timestamp":1761133855000},"source":"Crossref","is-referenced-by-count":3,"title":["Trends in utilization of advanced therapies in patients with inflammatory bowel diseases in the USA, 2021-2025"],"prefix":"10.1093","volume":"19","author":[{"given":"Siddharth","family":"Singh","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic Arizona , Scottsdale, AZ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6604-7712","authenticated-orcid":false,"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network , Pittsburgh, PA,","place":["United States"]},{"name":"Department of Medicine, Drexel University College of Medicine , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Goodwin","sequence":"additional","affiliation":[{"name":"Department of Medicine, London Health Sciences Centre Research Institute , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1092-0033","authenticated-orcid":false,"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Western University , London, ON,","place":["Canada"]},{"name":"Department of Epidemiology and Biostatistics, Western University , London, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gursimran","family":"Kochhar","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Hepatology & Nutrition, Allegheny Health Network , Pittsburgh, PA,","place":["United States"]},{"name":"Department of Medicine, Drexel University College of Medicine , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2025111402315584500_jjaf186-B1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature"},{"key":"2025111402315584500_jjaf186-B2","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn\u2019s disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"key":"2025111402315584500_jjaf186-B3","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0140-6736(23)00966-2","article-title":"Ulcerative colitis","volume":"402","author":"Le Berre","year":"2023","journal-title":"Lancet"},{"key":"2025111402315584500_jjaf186-B4","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"key":"2025111402315584500_jjaf186-B5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/sim.9669","article-title":"In praise of Prais-Winsten: an evaluation of methods used to account for autocorrelation in interrupted time series","volume":"42","author":"Bottomley","year":"2023","journal-title":"Stat Med"},{"key":"2025111402315584500_jjaf186-B6","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: a systematic literature review","volume":"14","author":"Lubloy","year":"2014","journal-title":"BMC Health Serv Res"},{"key":"2025111402315584500_jjaf186-B7","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","article-title":"Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 American Gastroenterological Association Evidence Synthesis","volume":"167","author":"Ananthakrishnan","year":"2024","journal-title":"Gastroenterology"},{"key":"2025111402315584500_jjaf186-B8","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.14309\/ajg.0000000000003406","article-title":"IL-23p19 antagonists vs ustekinumab for treatment of Crohn\u2019s disease: a meta-analysis of randomized controlled trials","volume":"120","author":"Dziegielewski","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2025111402315584500_jjaf186-B9","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/pharmaceutics16050629","article-title":"Trends in targeted therapy usage in inflammatory bowel disease: TRENDY Study of ENEIDA","volume":"16","author":"Gomez-Labrador","year":"2024","journal-title":"Pharmaceutics"},{"key":"2025111402315584500_jjaf186-B10","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/ecco-jcc\/jjad203","article-title":"Biologic therapy for inflammatory bowel disease: real-world comparative effectiveness and impact of drug sequencing in 13 222 patients within the UK IBD BioResource","volume":"18","author":"Kapizioni","year":"2024","journal-title":"J Crohns Colitis"}],"container-title":["Journal of Crohn\u2019s and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf186\/64925034\/jjaf186.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/10\/jjaf186\/64925034\/jjaf186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/10\/jjaf186\/64925034\/jjaf186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T07:32:03Z","timestamp":1763105523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf186\/8300979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":10,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,11,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf186","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]},"article-number":"jjaf186"}}